Welcome to our dedicated page for INVO BioScience news (Ticker: INVO), a resource for investors and traders seeking the latest updates and insights on INVO BioScience stock.
INVO Bioscience, Inc. (Nasdaq: INVO) is a healthcare services company dedicated to expanding access to advanced reproductive technology. Specializing in fertility treatment, INVO focuses on making fertility care more accessible and inclusive. The company operates through dedicated fertility clinics called INVO Centers, and also acquires profitable in vitro fertilization (IVF) clinics in the United States. Their proprietary technology, the INVOcell® device, allows fertilization and early embryo development to occur within a woman's body, a groundbreaking method known as Intravaginal Culture (IVC).
INVO Bioscience's recent strategic initiatives have included the acquisition of US-based IVF clinics and the opening of three INVO Centers in North America. The company's commercial strategy is built around selling products directly to physicians, and via distributors to IVF centers and medical practices.
On October 23, 2023, INVO announced a definitive merger agreement with NAYA Biosciences Inc. The merger, an all-stock transaction, aims to form a combined entity named NAYA Biosciences, which will operate under a NASDAQ listing. The merged company will focus on fertility, oncology, and regenerative medicine, leveraging NAYA's capabilities in cell and gene therapy, and artificial intelligence.
The merger is expected to provide INVO with new capital to expand its fertility clinic network across the United States and advance NAYA's oncology therapeutics. This agreement is a major step forward, with NAYA's shareholders set to own approximately 88% of the combined company and INVO shareholders 12%, pending shareholder approval and other conditions.
Financially, INVO Bioscience has shown a strong performance with significant revenue growth. For the three months ended September 30, 2023, the company reported a revenue increase of 314% compared to the same period in 2022. The company's ongoing strategic focus aims at achieving profitability by 2024, fueled by growth from its INVO Centers and efficient management of operating expenses.
INVO Bioscience is committed to making advanced fertility treatments more affordable and accessible worldwide, offering a natural and less invasive alternative to traditional IVF methods with the INVOcell® device.
INVO Bioscience (NASDAQ: INVO) has appointed Meryle Lynn Chamberlain as the new Director of Marketing to enhance its global brand strategy for INVOcell, the world's only in vivo Intravaginal Culture System. With over 15 years in women's health marketing, Chamberlain aims to expand the accessibility of affordable fertility treatments. CEO Steve Shum expressed optimism about strengthening marketing strategies alongside new board member Rebecca Messina, previously CMO at Uber. This leadership change is positioned as a crucial step towards the commercialization and adoption of INVOcell in the fertility market.
INVO Bioscience, Inc. (NASDAQ: INVO) announced the appointment of Rebecca Messina to its board of directors, effective immediately. Messina brings extensive marketing experience from firms like Uber and Coca-Cola, focusing on brand building and strategic growth. CEO Steve Shum highlighted that her appointment aligns with the company's mission to enhance access to fertility treatment globally through its innovative device, INVOcell®, which offers a cost-effective alternative to traditional methods. Messina expressed her commitment to broadening awareness of fertility options.
INVO Bioscience (NASDAQ: INVO) announced its support for RESOLVE: The National Infertility Association during National Infertility Awareness Week (April 18-24). The company focuses on providing affordable infertility treatments with its INVOcell®, the only in vivo Intravaginal Culture System. CEO Steve Shum emphasized the importance of increasing access to care for the underserved patient population facing infertility challenges. RESOLVE advocates for equal access to family building options and connects individuals with resources for infertility.
INVO Bioscience (NASDAQ: INVO) has announced a partnership with Lyfe Medical to expand the accessibility of its INVOcell infertility treatment in Northern California, home to approximately 8 million residents. Under the agreement, Lyfe Medical will operate a clinic in the San Francisco Bay Area, while INVO Bioscience will establish an embryology center to support the INVO procedure. The partnership aims to address challenges in affordability and capacity within the infertility treatment sector, enhancing patient access to care.
INVO Bioscience, a medical device company specializing in infertility treatments, announced that CEO Steve Shum will present at the Tribe Public Webinar titled "Democratizing Infertility - A Severely Underserved Global Market". This event will be held on April 13, 2021, at 8:30 am Pacific / 11:30 am Eastern. Attendees can register for the complimentary webinar via INVO.TribePublic.com and submit questions to management either beforehand or during the session.
INVO Bioscience, Inc. (NASDAQ: INVO) reported a revenue of $1.04 million for 2020, down from $1.48 million in 2019, with a net loss of $8.3 million driven by higher operating expenses. The company announced plans to open its first U.S. INVOcell clinic in Birmingham, Alabama, in partnership with experienced reproductive specialists, with additional clinics planned in Mexico and India. A $501,000 purchase order from Ferring, placed in March 2021, will boost revenue in Q1. Cash reserves stand at $10.1 million, reflecting a significant increase from $1.2 million in 2019.
INVO Bioscience (NASDAQ: INVO) announced its participation in the Lytham Partners Spring 2021 Investor Conference on April 1, 2021, at 4:15 PM ET. The company specializes in the INVOcell®, the world's first in vivo Intravaginal Culture System designed for infertility treatments. A webcast of the presentation will be accessible on the company's website and archived for later viewing. Management will engage in virtual one-on-one meetings during the conference period from March 30 to April 1, 2021. For details, visit invobioscience.com.
INVO Bioscience (NASDAQ: INVO) is set to report its fourth quarter and fiscal year 2020 financial results on March 30, 2021, after market close. The company specializes in developing the INVOcell®, the only in vivo Intravaginal Culture System (IVC) designed to assist patients with infertility. A conference call will be held on the same day at 4:30 pm ET for a comprehensive review of the outcomes. The aim of INVO is to provide affordable and effective treatments for infertility, leveraging their innovative procedures and technology.
INVO Bioscience, Inc. (NASDAQ: INVO) has signed a 50/50 joint venture agreement with reproductive specialists to establish the first INVO-exclusive clinic in the U.S. located in Birmingham, Alabama. This clinic aims to enhance the accessibility and affordability of infertility treatment using the INVOcell, an innovative in vivo Intravaginal Culture System. Operations are expected to begin in the second half of 2021. The collaboration with experienced professionals is anticipated to drive adoption of the INVOcell technology, potentially benefiting many underserved patients.
INVO Bioscience (NASDAQ: INVO), a medical device company specializing in infertility treatments, will participate in the 33rd Annual ROTH Conference held virtually from March 15-17, 2021. The company will engage in one-on-one meetings with investors and analysts to discuss its innovative product, INVOcell, the only in vivo Intravaginal Culture System. This product offers a more affordable and natural approach to infertility treatment compared to traditional methods like IVF. An investor presentation will be available at their website.
FAQ
What is the current stock price of INVO BioScience (INVO)?
What is the market cap of INVO BioScience (INVO)?
What is the primary focus of INVO Bioscience?
What is the INVOcell® device?
What recent strategic initiative did INVO Bioscience undertake?
How many INVO Centers are currently operational in North America?
What are the expected benefits of the merger with NAYA Biosciences?
What financial performance did INVO Bioscience report for Q3 2023?
What is the anticipated timeline for INVO Bioscience to achieve profitability?
Who will lead the combined company after the merger with NAYA Biosciences?
What are the main areas of focus for the combined NAYA Biosciences?
Where can shareholders find more information about the proposed merger?
